Key points are not available for this paper at this time.
Abstract Aim The trial (NCT04016974) investigated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide, the first orally administered glucagon‐like peptide‐1 analogue for type 2 diabetes, in healthy Chinese subjects. Materials and Methods This single‐centre, multiple‐dose, placebo‐controlled trial randomized 32 healthy Chinese adults to once‐daily oral semaglutide (3 mg escalating to 14 mg) or placebo for 12 weeks. Blood samples were collected regularly during treatment and follow‐up. The primary endpoint was the area under the semaglutide concentration–time curve over a dosing interval (0‐24 h) at steady state (AUC 0‐24h,sema,SS ). Secondary pharmacokinetic endpoints included the maximum observed semaglutide plasma concentration at steady state (C max,sema,SS ). Supportive secondary pharmacodynamics endpoints included changes in body weight and fasting plasma glucose. Results Treatment with all oral semaglutide doses showed dose‐dependent increases in semaglutide exposure in healthy Chinese subjects at steady state, determined by AUC 0‐24h,sema,SS (233, 552 and 1288 h·nmol/L for 3, 7 and 14 mg of oral semaglutide, respectively) and C max,sema,SS . Oral semaglutide treatment was associated with significant reductions in body weight ( p = .0001) and fasting plasma glucose ( p = .0011) versus placebo at the end of treatment. The safety and tolerability of oral semaglutide were consistent with the known profile of glucagon‐like peptide‐1 receptor agonists, with no severe or blood‐glucose–confirmed symptomatic hypoglycaemic events, serious adverse events or deaths. The most frequent adverse events were gastrointestinal disorders. Conclusions At steady state, oral semaglutide exposure was dose dependent and close to dose proportionality in healthy Chinese subjects. This is consistent with previous clinical pharmacology results for oral semaglutide.
Xie et al. (Wed,) studied this question.